1. Australia Stocks

  2. •

    Process industries

  3. •

    Agricultural commodities/Milling
Ecs Botanics Holdings Ltd

Ecs Botanics Holdings Ltd

AASX:ECS
0.01
AUD
0.00
(0.00%)
0.00EPS
9.98P/E
21.91MMarket Cap
Mar 04Next Earn
Ecs Botanics Holdings Ltd
ASX:ECS
(Australian Securities Exchange)

Recent

price

0.01

P/E

ratio

9.98

div

yld

- -

ROIC.AI

2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
AUD
1.79
2.57
3.63
2.4
1.92
1.26
0.6
- -
- -
- -
- -
- -
- -
0.01
0.01
0.02
Revenue per Share
-2.7
-0.21
-1.21
-0.33
-0.28
-0.1
0.3
-0.01
-0.01
- -
-0.01
-0.01
-0.01
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
1.04
1.82
0.8
0.27
-0.01
-0.07
0.02
0.01
0.01
- -
- -
0.01
0.02
0.02
0.02
0.02
Book Value per Share
0.23
-0.6
-1.14
-0.75
-0.42
-0.28
0.02
0.01
0.01
- -
- -
0.01
0.02
0.02
0.02
0.02
Tangible Book Value per Share
3
8
16
24
27
29
29
29
31
44
41
508
676
1,029
1,107
1,168
Basic Weighted Avg Shares
5
21
60
57
51
36
18
- -
- -
- -
- -
1
1
7
15
20
Sales/Revenue/Turnover
-37.74
-8.53
-7.29
-3.04
-5.87
-10.86
-10.48
-517.85
- -
- -
- -
-545.78
-396.69
-12.14
-0.45
8.68
Operating Margin (%)
- -
- -
1
1
1
1
1
- -
- -
- -
- -
- -
- -
1
1
1
Depreciation Expense
-8
-2
-20
-8
-7
-3
9
- -
- -
- -
-1
-5
-4
-1
- -
2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-151.11
-8.11
-33.41
-13.78
-14.53
-8.36
50.38
-517.44
- -
- -
- -
-546.09
-347.79
-16.96
-0.53
9.94
Profit Margin (%)
1
-18
-7
-2
-6
- -
1
- -
- -
- -
- -
3
7
13
9
15
Working Capital
- -
7
19
18
12
13
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
LT Debt
6
29
17
7
- -
-2
1
- -
- -
- -
- -
5
17
22
22
28
Total Equity
- -
- -
- -
- -
- -
- -
-26.46
- -
- -
- -
- -
- -
- -
- -
-3.54
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
132.17
- -
- -
- -
- -
- -
- -
- -
-0.18
- -
Return on Capital (%)
-90.02
-9.93
-87.2
-64.43
- -
- -
- -
-70.88
-72.51
-73.43
- -
- -
-39.19
-5.86
-0.37
7.9
Return on Common Equity (%)

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-412.2%
-748.35%
27.07%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
-237.99%
-399.99%
-2,534.21%
Sales/Revenue/Turnover
- -
- -
30.16%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
7
2023
- -
- -
15
2024
- -
- -
20

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2022
- -
- -
- -
2023
- -
- -
- -
2024
- -
- -
- -
Similar Companies
Patanjali Foods Limited (NSE:PATANJALI)
Tilray Brands, Inc. (NASDAQ:TLRY)
Archer-Daniels-Midland Company (NYSE:ADM)
Corteva, Inc. (NYSE:CTVA)
Canopy Growth Corporation (NASDAQ:CGC)
Balrampur Chini Mills Ltd (NSE:BALRAMCHIN)
Business
ECS Botanics Holdings Ltd (ASX:ECS) is an Australia-based medicinal cannabis cultivator and manufacturer headquartered in Murrabit West, Victoria, with operations utilizing progressive, regenerative, and organic horticultural practices powered by renewable energy sources; the company, founded in 2018, is licensed by the Therapeutic Goods Administration to produce PIC/S GMP and EU GMP certified products for domestic and international markets. It specializes as a B2B pharmaceutical manufacturer, cultivating high-quality cannabis strains including Sativa and Indica dominant varieties (18-25% THC), balanced CBD:THC ratios, and CBD-only options; these are processed into dried and trimmed flower for inhalation or medical use, or further extracted into resin for formulation into oils, capsules, and bespoke products supplied to strategic global partners. The company supplies markets in Australia, the United Kingdom, and other regions with medicinal cannabis programs, targeting pharmaceutical distributors, healthcare providers, and export partners through its subsidiaries ECS Botanics MC Pty Ltd and Flowerday Farms Pty Ltd. Recent developments include achieving positive net operating cash flow of A$140,000 in the September 2025 quarter, marking a A$1.6 million improvement from the prior period, driven by strong B2C sales via a one-year agreement with Elite Medical Solutions and the launch of the RAP brand alongside established B2B channels. In April 2025, ECS secured additional growth funding by increasing its National Australia Bank loan facility to A$5.2 million to support international launches of Terphogz cannabis products and expanded its GMP license to cover packaging, labeling, storage, and white-label manufacturing. The company reported a 50% increase in cannabis flower yields from redesigned protective crop enclosures, producing 656kg wet weight in its first harvest, and ordered nine new enclosures to boost premium dried flower output by over 200% to meet rising export and domestic demand; earlier milestones encompass a A$24 million five-year supply deal with MediCann Health (commenced 2024), resin agreements with Cannvalate and Sun Pharma, and first UK shipments to Lyphe Group.